Form 4: Moderna CFO James Mock Reports Stock Transactions

Moderna's CFO, James Mock, reported the conversion of restricted stock units into common stock and subsequent sale of shares for tax obligations.

Summary

• James M. Mock, Moderna's Chief Financial Officer, reported transactions involving company common stock and restricted stock units (RSUs).
• On October 3, 2025, 1,453 restricted stock units converted into common stock.
• On the same date, 703 shares of common stock were disposed of at a price of $28.37 per share to satisfy tax withholding obligations related to the RSU vesting.
• These transactions were conducted pursuant to a Rule 10b5-1 plan.
• Following these reported transactions, Mock directly owns 18,259 shares of Moderna common stock.
• Mock also directly holds 5,811 restricted stock units, which are subject to a vesting schedule where 25% vested on October 5, 2023, and the remainder vests in twelve equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent tax-related share disposition, which is a neutral event for company fundamentals.

Positives

• The vesting of 1,453 restricted stock units indicates a realization of compensation for the Chief Financial Officer.
• Transactions were executed under a Rule 10b5-1 plan, which suggests pre-scheduled and automated trading, often viewed favorably as it mitigates concerns about opportunistic insider trading.

Negatives

• The disposition of 703 shares to cover tax withholding obligations results in a reduction of the Chief Financial Officer's direct common stock holdings.

Future Outlook

The remaining 5,811 restricted stock units will vest in twelve equal quarterly installments following the initial 25% vesting on October 5, 2023, indicating future potential common stock acquisitions for the reporting person.

Industry Context

This filing is a routine insider transaction report specific to an executive's compensation and does not provide information on broader industry trends or the competitive landscape.

Stakeholder Impact

• Minimal direct impact on shareholders, as these are routine executive compensation transactions.
• Employees, customers, suppliers, and creditors are not directly impacted by this specific filing.

Next Steps

• Remaining restricted stock units will vest in twelve equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent sale of shares for tax purposes. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation.

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Transactions, RSU, Restricted Stock Units, CFO, James Mock, Executive Compensation, Rule 10b5-1